Abbott forecasts in line annual profit on medical device sales
Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitoring products.
Abbott’s 2025 Profit Forecast Meets Estimates on Device Demand
Abbott Laboratories is forecasting profit for 2025 in line with Wall Street’s estimates as the health care company said strong demand for its medical devices will continue to drive growth.
Abbott Laboratories Q4 Profit Increases, Inline With Estimates
Abbott Laboratories (ABT) revealed a profit for its fourth quarter that increased from last year in line with the Street estimates.
Abbott's first-quarter profit forecast misses estimates, shares dip
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more than 2% in premarket trading.
Abbott Recovers After First-Quarter Outlook Misses Estimates
Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street estimates as the health care company points to strong demand for its medical devices as a growth driver this year.
Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit
Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line profit.
Abbott forecasts first-quarter profit below estimates
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter sales in segments other than medical devices, sending its shares down 1% in premarket trading.
Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates
Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.
Abbott (ABT) Q4 Earnings Meet Estimates
Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.
FierceBiotech2d
Abbott posts 2024 medical device sales gains following structural heart, CGM launches
For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...
MassDevice2d
Abbott sales come up just shy of Q4 expectations on Wall Street, highlights EP growth
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Why Is Abbott Stock Trading Higher On Thursday?
Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...
Rubber and Plastics News4h
R.D. Abbott's NovationSi adds color to Arburg cell at MD&M West
NovationSi, the manufacturing subsidiary for California-based R.D. Abbott Co. Inc., will supply the colorant for a cell ...
Strong Performance and Promising Growth: Rick Wise’s Buy Rating on Abbott Laboratories
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
bovnews2d
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
MassDevice9d
The top 10 cardiac device stories of 2024
Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...
Abbott Banks on Glucose Monitors, New Launches to Ride Out China, Currency Hit
(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...